BlossomHill Therapeutics, Inc. BLSM PHARMA
Company Overview
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.
Why Investors Should Care
Generates a return on equity of 46.0%, reflecting efficient use of shareholder capital.
Carries low leverage with a debt-to-equity ratio of 0.22.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR -97.3%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | -97.28% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +37.56% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | - |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- RSI (14)78.33 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 46.0%.
CONS
- Earnings shrank at -97.3% CAGR over 5 years.
- RSI at 78 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BLSM BlossomHill Therapeutics, Inc. PHARMA | 22.01 | -9.02 | $640.08M | 0.00% | -43.41% | 45.97% | - | -97.28% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 11.45M | 22.11M |
| Operating Income | -11.45M | -22.11M |
| EBITDA | -11.37M | -21.98M |
| Interest Expense | - | - |
| Pretax Income | -10.48M | -21.01M |
| Tax Provision | - | - |
| Net Income | -10.48M | -21.01M |
| Diluted EPS | -0.36 | -0.72 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 36.40M | 64.02M |
| Operating Income | -36.40M | -64.02M |
| EBITDA | -36.05M | -63.58M |
| Interest Expense | - | - |
| Pretax Income | -30.70M | -60.55M |
| Tax Provision | - | - |
| Net Income | -30.70M | -60.55M |
| Diluted EPS | -1.06 | -2.08 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 106.78M | 162.97M |
| Current Assets | 104.17M | 138.83M |
| Cash & Equivalents | 100.15M | 136.68M |
| Inventory | - | - |
| Receivables | - | - |
| Total Liabilities | 179.66M | 294.70M |
| Current Liabilities | 6.77M | 15.48M |
| Long Term Debt | - | - |
| Total Debt | 525.00K | 22.40M |
| Total Equity | -72.88M | -131.73M |
| Shares Outstanding | 29.08M | 29.08M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -31.42M | -46.92M |
| Investing Cash Flow | -92.00K | -1.07M |
| Financing Cash Flow | 17.56M | 84.53M |
| Capital Expenditure | -92.00K | -1.07M |
| Free Cash Flow | -31.51M | -47.99M |
| Net Change in Cash | -13.95M | 36.53M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | 42.1% | 46.0% |
| ROCE % | -36.4% | -43.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BLSM
BlossomHill Therapeutics (NASDAQ:BLSM) Stock Rating Upgraded by Guggenheim - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPUlpjQldwMDQ2X3huTndzSVBuUnNCeFRkOEhDdGVxemZLeUlyY1o1ellfVVV1WFV1MVU3Uy1EcHZuS2lEbkxUbEFFSlZ5Mm9oMXNWVU5uUUFqOGxMOG03dmdfSXF6SjBuZ2g5RVdSemlUcEplV20xcDRTZUJCa2Z3aEt6eVRIN3dhNlZCcG…
Patients whose lung cancer develops a specific resistance mutation after a targeted drug stops working have no approved pills aimed at it. BlossomHill Therapeutics plans to present updated trial data on Sept. 15. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOVGhyUDJNSC1FRTdxRVhJS3ljejM1TzBWY04wOWgxODY4eVVweDNwSlJtUGltRUpSaUxPVm1YRXdTZHNDWEJpclViYUUxTmFlSkxRc2ZaendwZU9PaHR1VTFkV1M0TzNJaTdOYVRmZGNsQWF1M2tTNVlhQk4wdl9CcjFReFFuMmlrVDJicm…
BlossomHill Therapeutics, Inc. - Common Stock (Nasdaq:BLSM) Stock Quote - The Chronicle-Journal
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxNZng5WDBFemk2el9obDlrNXpYWmVRQUNxWXBhRk1pU2xHc0tRY1psM0ZFRmlPT1psSTNlbUp2bUNOOWx2ZU5QVVVLcTJUdEdnSnFLcC15TzVnVkJwaVJYV2l1aDh0c0h1aGhNaEh2cVZrSlZMTFFhMjZGUnhPMDM0UGtn?oc=5" target=…
BLSM - BlossomHill Therapeutics Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9OOEw2VWxhQWJzNzhkYjhJd19ZWEhnb1Q1a3YxNHZOdXhQMFNTNlctM3ZRNnlSRklKWVFoMGpGSXJjTWtWRFE?oc=5" target="_blank">BLSM - BlossomHill Therapeutics Inc Stock Price and Quote</a>  …
BlossomHill Therapeutics (NASDAQ:BLSM) Shares Gap Up - Here's Why - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNUzZiY0YxZ1RwU1lhc2xHdUV3RXdGZVMtbDlNTTBqd2l1QnpjSnBwU0lkbGtGMC1aRy03ZC1pYm85cDMxNDlLbENESDlHT2xhMFdfdWFLUWVKMHhsREJ2QWdacUpJcDZCemliUFVvR1VRN2lLS2FfOTRfYkFpbGp0aE5jb1piWmdkMUlqb0…
BlossomHill (NASDAQ: BLSM) insider buys at $16 and gets options - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQS1pMT0huMHlFNE0xS0lMczBfN0dfUlZleDJnR1p6T2hzVU1hMXlCTVhLWHN2b24zNXQ5N24xNTItN1FHbDhQX3EtTUxKR0J6X0xUYWs2T0lfOVYyZ0xmUm01RkM1c2NFdnVmSktBckJOQUlpTkMxMy1FcEt2N0h5eGVpck5IWklXWERDcU…
BLSM — Frequently Asked Questions
What is the current share price of BlossomHill Therapeutics, Inc. (BLSM)?
As of 2026-09-07 16:24 PDT, BlossomHill Therapeutics, Inc. (BLSM) trades at $22.01 on NasdaqGS. Its 52-week range is $15.80 to $22.01.
What is the market capitalisation of BLSM?
BlossomHill Therapeutics, Inc. (BLSM) has a market capitalisation of $640.08M on NasdaqGS.
What is the P/E ratio of BLSM?
BLSM trades at a trailing price-to-earnings (P/E) ratio of -9.02. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -4.86.
What is the return on equity (ROE) of BLSM?
BLSM has a return on equity (ROE) of 45.97%. Its return on capital employed (ROCE) is -43.41%.
Is BLSM a good stock to buy?
This page provides a data-driven analysis of BlossomHill Therapeutics, Inc. (BLSM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.